BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

524 related articles for article (PubMed ID: 27639593)

  • 1. Steatosis induced CCL5 contributes to early-stage liver fibrosis in nonalcoholic fatty liver disease progress.
    Li BH; He FP; Yang X; Chen YW; Fan JG
    Transl Res; 2017 Feb; 180():103-117.e4. PubMed ID: 27639593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CCL20 is up-regulated in non-alcoholic fatty liver disease fibrosis and is produced by hepatic stellate cells in response to fatty acid loading.
    Chu X; Jin Q; Chen H; Wood GC; Petrick A; Strodel W; Gabrielsen J; Benotti P; Mirshahi T; Carey DJ; Still CD; DiStefano JK; Gerhard GS
    J Transl Med; 2018 Apr; 16(1):108. PubMed ID: 29690903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LPS-induced TNF-α factor mediates pro-inflammatory and pro-fibrogenic pattern in non-alcoholic fatty liver disease.
    Ceccarelli S; Panera N; Mina M; Gnani D; De Stefanis C; Crudele A; Rychlicki C; Petrini S; Bruscalupi G; Agostinelli L; Stronati L; Cucchiara S; Musso G; Furlanello C; Svegliati-Baroni G; Nobili V; Alisi A
    Oncotarget; 2015 Dec; 6(39):41434-52. PubMed ID: 26573228
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-throughput sequencing reveals altered expression of hepatic microRNAs in nonalcoholic fatty liver disease-related fibrosis.
    Leti F; Malenica I; Doshi M; Courtright A; Van Keuren-Jensen K; Legendre C; Still CD; Gerhard GS; DiStefano JK
    Transl Res; 2015 Sep; 166(3):304-14. PubMed ID: 26001595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hepatic stellate cells secrete Ccl5 to induce hepatocyte steatosis.
    Kim BM; Abdelfattah AM; Vasan R; Fuchs BC; Choi MY
    Sci Rep; 2018 May; 8(1):7499. PubMed ID: 29760499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A20 Attenuates Liver Fibrosis in NAFLD and Inhibits Inflammation Responses.
    Wang X; Ai L; Xu Q; Wu C; Chen Z; Su D; Jiang X; Fan Z
    Inflammation; 2017 Jun; 40(3):840-848. PubMed ID: 28251449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibronectin Type III Domain-Containing Protein 5 rs3480 A>G Polymorphism, Irisin, and Liver Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
    Petta S; Valenti L; Svegliati-Baroni G; Ruscica M; Pipitone RM; Dongiovanni P; Rychlicki C; Ferri N; Cammà C; Fracanzani AL; Pierantonelli I; Di Marco V; Meroni M; Giordano D; Grimaudo S; Maggioni M; Cabibi D; Fargion S; Craxì A
    J Clin Endocrinol Metab; 2017 Aug; 102(8):2660-2669. PubMed ID: 28472477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extracellular vesicles derived from fat-laden hepatocytes undergoing chemical hypoxia promote a pro-fibrotic phenotype in hepatic stellate cells.
    Hernández A; Reyes D; Geng Y; Arab JP; Cabrera D; Sepulveda R; Solis N; Buist-Homan M; Arrese M; Moshage H
    Biochim Biophys Acta Mol Basis Dis; 2020 Oct; 1866(10):165857. PubMed ID: 32512191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CXC Motif Ligand 16 Promotes Nonalcoholic Fatty Liver Disease Progression via Hepatocyte-Stellate Cell Crosstalk.
    Jiang L; Yang M; Li X; Wang Y; Zhou G; Zhao J
    J Clin Endocrinol Metab; 2018 Nov; 103(11):3974-3985. PubMed ID: 30053055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sorafenib reduces steatosis-induced fibrogenesis in a human 3D co-culture model of non-alcoholic fatty liver disease.
    Romualdo GR; Da Silva TC; de Albuquerque Landi MF; Morais JÁ; Barbisan LF; Vinken M; Oliveira CP; Cogliati B
    Environ Toxicol; 2021 Feb; 36(2):168-176. PubMed ID: 32918399
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identifying nonalcoholic fatty liver disease patients with active fibrosis by measuring extracellular matrix remodeling rates in tissue and blood.
    Decaris ML; Li KW; Emson CL; Gatmaitan M; Liu S; Wang Y; Nyangau E; Colangelo M; Angel TE; Beysen C; Cui J; Hernandez C; Lazaro L; Brenner DA; Turner SM; Hellerstein MK; Loomba R
    Hepatology; 2017 Jan; 65(1):78-88. PubMed ID: 27706836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of STING Is Increased in Liver Tissues From Patients With NAFLD and Promotes Macrophage-Mediated Hepatic Inflammation and Fibrosis in Mice.
    Luo X; Li H; Ma L; Zhou J; Guo X; Woo SL; Pei Y; Knight LR; Deveau M; Chen Y; Qian X; Xiao X; Li Q; Chen X; Huo Y; McDaniel K; Francis H; Glaser S; Meng F; Alpini G; Wu C
    Gastroenterology; 2018 Dec; 155(6):1971-1984.e4. PubMed ID: 30213555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemokine ligand 20 (CCL20) expression increases with NAFLD stage and hepatic stellate cell activation and is regulated by miR-590-5p.
    Hanson A; Piras IS; Wilhelmsen D; Still CD; Chu X; Petrick A; Gerhard GS; DiStefano JK
    Cytokine; 2019 Nov; 123():154789. PubMed ID: 31352173
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolactin improves hepatic steatosis via CD36 pathway.
    Zhang P; Ge Z; Wang H; Feng W; Sun X; Chu X; Jiang C; Wang Y; Zhu D; Bi Y
    J Hepatol; 2018 Jun; 68(6):1247-1255. PubMed ID: 29452209
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fatty Acids Activate the Transcriptional Coactivator YAP1 to Promote Liver Fibrosis via p38 Mitogen-Activated Protein Kinase.
    Salloum S; Jeyarajan AJ; Kruger AJ; Holmes JA; Shao T; Sojoodi M; Kim MH; Zhuo Z; Shroff SG; Kassa A; Corey KE; Khan SK; Lin W; Alatrakchi N; Schaefer EAK; Chung RT
    Cell Mol Gastroenterol Hepatol; 2021; 12(4):1297-1310. PubMed ID: 34118488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypoxia inducible factor-1 promotes liver fibrosis in nonalcoholic fatty liver disease by activating PTEN/p65 signaling pathway.
    Han J; He Y; Zhao H; Xu X
    J Cell Biochem; 2019 Sep; 120(9):14735-14744. PubMed ID: 31009107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted Delivery of Stk25 Antisense Oligonucleotides to Hepatocytes Protects Mice Against Nonalcoholic Fatty Liver Disease.
    Cansby E; Nuñez-Durán E; Magnusson E; Amrutkar M; Booten SL; Kulkarni NM; Svensson LT; Borén J; Marschall HU; Aghajan M; Mahlapuu M
    Cell Mol Gastroenterol Hepatol; 2019; 7(3):597-618. PubMed ID: 30576769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antagonism of the chemokine Ccl5 ameliorates experimental liver fibrosis in mice.
    Berres ML; Koenen RR; Rueland A; Zaldivar MM; Heinrichs D; Sahin H; Schmitz P; Streetz KL; Berg T; Gassler N; Weiskirchen R; Proudfoot A; Weber C; Trautwein C; Wasmuth HE
    J Clin Invest; 2010 Nov; 120(11):4129-40. PubMed ID: 20978355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Trajectories of Liver Fibrosis and Gene Expression Profiles in Nonalcoholic Fatty Liver Disease Associated With Diabetes.
    Sako S; Takeshita Y; Takayama H; Goto H; Nakano Y; Ando H; Tsujiguchi H; Yamashita T; Arai K; Kaneko S; Nakamura H; Harada K; Honda M; Takamura T
    Diabetes; 2023 Sep; 72(9):1297-1306. PubMed ID: 37343270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Activating transcription factor 3 is a target molecule linking hepatic steatosis to impaired glucose homeostasis.
    Kim JY; Park KJ; Hwang JY; Kim GH; Lee D; Lee YJ; Song EH; Yoo MG; Kim BJ; Suh YH; Roh GS; Gao B; Kim W; Kim WH
    J Hepatol; 2017 Aug; 67(2):349-359. PubMed ID: 28365312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.